Every man over the age of 45 is at risk for prostate cancer. Two-dimensional (2D) trans rectal ultrasound (TRUS) guided biopsy is the standard method for prostate cancer diagnosis. A critical problem of this TRUS- guided biopsy approach is its significant sampling error and its low sensitivity (24%-52%). Current biopsy approaches may miss up to 30% of prostate cancer. Nevertheless, more than 1.2 million prostate biopsies are performed in each year and the biopsy cost is more than two billion dollars. Innovative image-guided biopsy technology that can improve cancer detection can have significant impact on the management of this disease that affects one in six men. The objective of the proposed study is to evaluate a new, molecular image directed, three-dimensional (3D) ultrasound guided biopsy system in human patients. At our NIH-funded Emory Molecular and Translational Imaging Center, it has been shown that PET/CT imaging with a new, PET molecular imaging agent i.e., FACBC, is more sensitive than the FDA-approved SPECT/CT in prostate cancer detection. FACBC images showed higher focal uptake in tumor foci than in normal prostate and thus could be ideal information to direct targeted biopsy of the prostate. This newly developed biopsy system has a unique feature that FACBC PET/CT images can be registered with 3D ultrasound images, as a result, a suspicious PET lesion is superimposed over the real-time ultrasound data;and the fused image is then used to direct biopsy needles to tumor targets. The hypothesis of the study is that FACBC PET/ultrasound fusion guided biopsy can detect more cancer per core than the standard 12-core TRUS guided biopsy.
The specific aims i nclude: 1) To develop the workflow for performing deformable registration and fusion of FACBC PET/CT and 3D ultrasound images of human patients, and 2) To perform FACBC PET/CT directed, 3D ultrasound-guided biopsy and determine if targeted fusion biopsy can detect more cancer than 2D TRUS-guided biopsy. Thirty six patients, who have suspicion of recurrent prostate cancer after definitive therapy such as radiotherapy, will be recruited into this study. Approximately hal of the patients will have positive imaging findings and will undergo 2D TRUS-guided biopsy as well as PET/ultrasound fusion biopsy. The proposed study will be the first-in-human trial that uses PET/CT imaging to direct 3D ultrasound-guided biopsy of the prostate. The multimodality imaging approach will combine the high sensitivity from PET and real-time information from ultrasound for improved cancer detection. This early-phase clinical trial will help transform the field from the current "blind" biopsy to future "targeted" biopsy and result in the change of prostate cancer management. The new biopsy technology can have an immediate impact on patient care by improving the detection and diagnosis of prostate cancer.

Public Health Relevance

This study aims to improve prostate cancer detection by using a new molecular imaging technology and by using a new three-dimensional image-guided system. By bringing PET/CT to the ultrasound suite, allowing highly sensitive imaging and targeting of suspicious lesions, the new system offers the potential to diagnose serious prostate cancers earlier and follow low-risk cancers more accurately than the standard, two- dimensional, trans rectal ultrasound guided biopsy method.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA176684-01
Application #
8509090
Study Section
Special Emphasis Panel (ZRG1-SBIB-W (56))
Program Officer
Henderson, Lori A
Project Start
2013-09-01
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
1
Fiscal Year
2013
Total Cost
$288,425
Indirect Cost
$80,925
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Lu, Guolan; Halig, Luma; Wang, Dongsheng et al. (2014) Spectral-Spatial Classification Using Tensor Modeling for Cancer Detection with Hyperspectral Imaging. Proc SPIE Int Soc Opt Eng 9034:903413
Lu, Guolan; Halig, Luma; Wang, Dongsheng et al. (2014) Hyperspectral Imaging for Cancer Surgical Margin Delineation: Registration of Hyperspectral and Histological Images. Proc SPIE Int Soc Opt Eng 9036:90360S
Qin, Xulei; Wang, Silun; Shen, Ming et al. (2014) Mapping Cardiac Fiber Orientations from High-Resolution DTI to High-Frequency 3D Ultrasound. Proc SPIE Int Soc Opt Eng 9036:90361O
Pike, Robert; Patton, Samuel K; Lu, Guolan et al. (2014) A Minimum Spanning Forest Based Hyperspectral Image Classification Method for Cancerous Tissue Detection. Proc SPIE Int Soc Opt Eng 9034:90341W
Lu, Guolan; Halig, Luma; Wang, Dongsheng et al. (2014) Spectral-spatial classification for noninvasive cancer detection using hyperspectral imaging. J Biomed Opt 19:106004
Qin, Xulei; Lu, Guolan; Sechopoulos, Ioannis et al. (2014) Breast Tissue Classification in Digital Tomosynthesis Images Based on Global Gradient Minimization and Texture Features. Proc SPIE Int Soc Opt Eng 9034:90341V
Qin, Xulei; Fei, Baowei (2014) Measuring myofiber orientations from high-frequency ultrasound images using multiscale decompositions. Phys Med Biol 59:3907-24
Wang, Dongsheng; Fei, Baowei; Halig, Luma V et al. (2014) Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 8:6620-32
Malliori, A; Bliznakova, K; Sechopoulos, I et al. (2014) Breast tomosynthesis with monochromatic beams: a feasibility study using Monte Carlo simulations. Phys Med Biol 59:4681-96
Sechopoulos, Ioannis; Bliznakova, Kristina; Fei, Baowei (2013) Power spectrum analysis of the x-ray scatter signal in mammography and breast tomosynthesis projections. Med Phys 40:101905

Showing the most recent 10 out of 11 publications